KarXT (xanomeline/trospium) is a novel muscarinic acetylcholine receptor agonist being developed by Bristol-Myers Squibb for the treatment of cognitive impairment associated with mild to moderate Alzheimer's disease. This Phase 3 clinical trial, known as MINDSET 1 (NCT06976216), is evaluating the efficacy and safety of KarXT in approximately 586 participants[1][2].
KarXT represents a fundamentally different approach to Alzheimer's disease therapy compared to existing treatments. Rather than inhibiting acetylcholinesterase enzymes (like donepezil or rivastigmine), KarXT directly activates muscarinic acetylcholine receptors, providing a more direct and potent stimulation of cholinergic signaling in the brain[3].
| Parameter | Value |
|---|---|
| NCT Number | NCT06976216 |
| Trial Name | MINDSET 1 |
| Phase | Phase 3 |
| Status | RECRUITING |
| Sponsor | Bristol-Myers Squibb |
| Enrollment | 586 participants (estimated) |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | July 14, 2025 |
| Completion Date | February 23, 2029 |
| Last Updated | March 5, 2026 |
KarXT is a unique combination of two compounds[1:1]:
This combination allows xanomeline to produce central muscarinic effects while trospium blocks peripheral muscarinic side effects, enabling doses that would otherwise cause intolerable autonomic adverse events.
| Receptor | Primary Location | Role in Cognition | KarXT Effect |
|---|---|---|---|
| M1 | Cortex, Hippocampus | Memory, learning, attention | Agonist - Direct activation |
| M4 | Striatum, Cortex | Antipsychotic-like effects | Agonist - Anti-agitation |
| M2 | Pre-synaptic terminals | Negative feedback | Antagonist - Reduced release |
| M3 | Peripheral organs | Autonomic function | Blocked by trospium |
The cholinergic system is severely compromised in Alzheimer's disease[3:1]:
Current cholinesterase inhibitors work by preventing acetylcholine breakdown, but their effect is limited by the reduced acetylcholine availability. Direct receptor activation bypasses this limitation by providing agonist activity regardless of endogenous acetylcholine levels.
The cholinergic hypothesis proposes that degeneration of cholinergic neurons in the basal forebrain and loss of cortical cholinergic innervation are primary contributors to the cognitive deficits in AD. This hypothesis has driven drug development for decades, leading to the development of acetylcholinesterase inhibitors.
However, these agents have modest efficacy, likely because they:
Direct muscarinic receptor agonists like xanomeline address these limitations by providing receptor-level stimulation independent of endogenous acetylcholine.
The muscarinic acetylcholine receptor family consists of five subtypes (M1-M5), all belonging to the G-protein coupled receptor superfamily:
Xanomeline's selectivity for M1 and M4 over M2/M3 provides cognitive benefits with reduced peripheral side effects.
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group clinical trial[4]. The MINDSET 1 trial is one of two pivotal Phase 3 trials (along with MINDSET 2, NCT06976203) designed to support regulatory approval.
| Arm | Treatment | Dose |
|---|---|---|
| 1 | KarXT (low dose) | 50/20 mg twice daily |
| 2 | KarXT (high dose) | 100/40 mg twice daily |
| 3 | Placebo | Matching tablets |
Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11): The primary cognitive endpoint measuring memory, language, praxis, and attention.
Clinician's Interview-Based Impression Plus Caregiver Input (CIBIC+): A global measure of clinical status that incorporates both clinician assessment and caregiver input.
In 2023, Bristol-Myers Squibb acquired Karuna Therapeutics for $14 billion, making KarXT one of the most valuable assets in the Alzheimer's disease pipeline[5]. This acquisition reflected the significant potential of KarXT based on:
The MINDSET trials represent Bristol-Myers Squibb's pivotal Phase 3 program for KarXT in Alzheimer's disease[6]:
This comprehensive development program aims to establish KarXT as a first-in-class muscarinic agonist for AD treatment.
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease[7]. The outcomes may:
KarXT would compete with existing AD therapies:
| Treatment | Mechanism | Efficacy | Limitations |
|---|---|---|---|
| Donepezil | AChE inhibitor | Moderate | Limited by acetylcholine availability |
| Memantine | NMDA antagonist | Modest | Symptomatic only |
| Aducanumab | Anti-amyloid antibody | Controversial | Amyloid reduction vs. clinical benefit |
| Lecanemab | Anti-amyloid antibody | Slows decline | ARIA risk, IV administration |
| KarXT | Muscarinic agonist | TBD | Peripheral side effects |
The trial is being conducted at multiple centers worldwide, including:
Xanomeline is a selective muscarinic receptor agonist with the following profile:
| Property | Value | Clinical Implication |
|---|---|---|
| Receptor affinity | M1 > M4 > M2/M3 | Cognitive benefits with peripheral sparing |
| Brain penetration | High | Effective central activity |
| Half-life | 4-6 hours | Twice-daily dosing required |
| Selectivity index | >10-fold M1 vs M3 | Low cholinergic side effects |
The selectivity for M1 and M4 receptors over M2 and M3 is critical because:
Trospium chloride is a quaternary ammonium compound with distinct properties:
| Property | Value | Clinical Implication |
|---|---|---|
| Blood-brain barrier penetration | Negligible | No central effects |
| Muscarinic affinity | M1-M5 non-selective | Blocks peripheral receptors |
| Half-life | 5-8 hours | Matches xanomeline timing |
| Excretion | Renal | Dose adjustment in renal impairment |
The combination ensures that xanomeline's central effects are maximized while peripheral muscarinic side effects are suppressed.
KarXT has minimal drug-drug interaction potential:
Phase 1 studies established:
The EMERALD program (Phase 2) demonstrated:
The successful schizophrenia data supports AD development because:
The 1:1:1 randomization to two dose levels vs. placebo provides:
ADAS-Cog11 Rationale:
CIBIC+ Rationale:
This duration is optimal for:
| Adverse Event | Incidence | Management |
|---|---|---|
| Nausea | 20-30% | Take with food, antiemetics |
| Vomiting | 10-15% | Dose adjustment |
| Dry mouth | 15-20% | Artificial saliva |
| Constipation | 10-15% | Laxatives |
| Urinary retention | 5-10% | Monitor, urology consult |
| Agent | Company | Mechanism | Development Status |
|---|---|---|---|
| KarXT | BMS | M1/M4 agonist | Phase 3 |
| Lucinamab | Eli Lilly | M1 positive allosteric modulator | Phase 1 |
| BRII-272 | Brii Biosciences | M1 agonist | Phase 1 |
KarXT would complement existing treatments:
| Category | Example | Mechanism | Limitation |
|---|---|---|---|
| AChEIs | Donepezil | Increase ACh | Limited efficacy |
| NMDA antagonist | Memantine | Block excitotoxicity | Modest effect |
| Anti-amyloid | Lecanemab | Clear plaques | ARIA risk |
| Muscarinic agonist | KarXT | Direct activation | Novel class |
Based on amyloid antibody precedents, KarXT could receive accelerated approval based on:
If approved for cognitive impairment, subsequent trials could pursue:
The trial could validate:
Future studies may explore:
KarXT (xanomeline/trospium) mechanism of action in Alzheimer's disease. 2024. ↩︎ ↩︎
Muscarinic acetylcholine receptor agonists for cognitive impairment. 2024. ↩︎
Cholinergic signaling in Alzheimer's disease pathogenesis. 2024. ↩︎ ↩︎
Clinical trial design in neurodegenerative disease (2023). 2023. ↩︎
Bristol-Myers Squibb acquisition of Karuna Therapeutics. 2023. ↩︎
Karuna Therapeutics pipeline and KarXT development. 2023. ↩︎
Future of Alzheimer's disease clinical trials (2024). 2024. ↩︎